Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep presents positive interim phase 2 TACTI-002 data at SITC (ASX:IMM)

IMMUTEP PRESENTS POSITIVE INTERIM DATA FROM PHASE II TACTI-002 TRIAL AT SITC Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trial Preliminary Ove...read more

Immutep Announce Results of Annual General Meeting (ASX:IMM)

Results of Annual General Meeting The results of Immutep Limited (ACN 009 237 889) (ASX:IMM) Annual General Meeting held earlier today are set out in the attached document. All resolutions were ...read more

Immutep - 2019 AGM CEO Presentation (ASX:IMM)

Immutep The Global leader in developing Lag-3 Therapeutics Annual General Meeting - November 2019 To view the presentation please download the attached PDF:

Immutep Annouce 2019 AGM Chairman's Address (ASX:IMM)

1 November 2019 Ladies and gentleman, On behalf of the Board, as Chairman I would like to welcome you to Immutep’s Annual General Meeting for 2019. Immutep is an Australian biotech that...read more

Immutep Announce Consolidation/Split (ASX:IMM)

Notification of Consolidation/Split For more information please download the attached PDF:

Immutep Announce Operational Update (ASX:IMM)

OPERATIONAL UPDATE TACTI-002 patient recruitment update Six patients now enrolled and dosed in INSIGHT-004, 6 mg cohort complete Significant eftilagimod alpha clinical data expecte...read more

Immutep Announce Change in substantial holding (ASX:IMM)

Form 604 Notice of change of interests of substantial holder For further information please download the attached PDF:

Immutep Announce Appendix 4C (ASX:IMM)

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B For further information please download the attached PDF:

US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy (ASX:IMU)

Sydney, Australia, 23 October 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced that prominent City of Hope researchers Yanghee Woo, MD, Associate Clinical Profe...read more

Imugene Announce CF33 Oncolytic Virus Clinical Trial Program Update (ASX:IMU)

SYDNEY Australia 21 October 2019: Imugene Limited (ASX: IMU) is pleased to provide an update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents coveri...read more

Imugene appoints Professor Yuman Fong, MD, of City of Hope to Chair Oncolytic Virotherapy Scientific Advisory Board (ASX:IMU)

Sydney, Australia, 17 October 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Professor Yuman Fong, MD, Chair of the Department of Surgery a...read more